Home Page  | Upcoming Events  |  Past Events  |  Registration  |   Attendees  |  More Info  |  LinkedIn
Combating Controlled Substance Abuse: Link Between CS Score and Health Outcomes 
  Download Brochure Need a brochure? Download the event brochure including a registration form you can fax or mail
During the past decade, drug overdose deaths have more than doubled and over 50 percent were related to prescription drugs. Increases in controlled substance prescribing have coincided with higher rates of misuse, abuse, hospitalizations and deaths. Right now, opioids cause more overdose deaths than heroin and cocaine combined.

To address this growing epidemic, Prime Therapeutics LLC has developed a controlled substance (CS) score that identifies high risk CS drug use. Through analysis of the CS score, Prime found a significant association between CS scores and health outcomes (hospitalizations and emergency room visits), CS drug costs, and total cost of care.  The CS score can help health plans identify and intervene with high risk members, and validating the CS score association with health care use and costs helps quantify the potential value of an intervention.

For this study, Prime reviewed claims from 11 million commercially insured members. Prime then analyzed a group of nearly 1 million of those members who were continuously enrolled in all of 2012 and 2013 with a CS score of 2.5 or higher (range 2.5 to 21). In terms of health care use and cost, Prime found that a one point increase in CS score is associated with: $1,488 higher total cost of care; $235 higher controlled substance drug cost; 0.9% increase in hospitalization rate; and 1.5% increase in emergency room visit rate.

Please join the Prime Therapeutics's Cathy Starner on Thursday, May 21st, 2015 at 1PM Eastern as she reviews the scope of the controlled substance abuse epidemic and a variety of methods to detect misuse and abuse, and then discusses the Prime CS Score study, its implications, and opportunities for stakeholders to lightly manage or aggressively manage the problem; during the Healthcare Web Summit event: Combating Controlled Substance Abuse.
Learning Objectives
Participants will be able to:
  1. Understand the scope of the controlled substance abuse epidemic.
  2. Review methods that can be utilized to identify potential high risk controlled substance users through medical and pharmacy administrative claims data.
  3. Provide an overview of pharmacy benefit management and health plan current controlled substance clinical programs and program outcomes.
  4. Describe ongoing effort for new clinical program development and collaborative efforts within the health insurance industry (e.g., fraud, waste, and abuse team; concurrent drug utilization review) and externally through non-profit organization collaboration (e.g., Alliance for Preventing the Abuse of Medicines).
  5. Consider opportunities for stakeholders to lightly manage or aggressively manage the problem.
  6. Engage in interactive learning through online question submission, attendee feedback and opportunity for follow-up questions, and networking with attendees, faculty and other professionals through a dedicated LinkedIn group.
Who Should Attend
Interested attendees would include:
  • C-Suite Executives
  • Pharmaceutical Directors
  • Medical Directors
  • Care Management Directors and Staff
  • Strategy and Planning Executives and Staff
  • Transformation and Innovation Executives and Staff
  • Clinical Analytics and Informatics Executives and Staff
  • Business Intelligence Analysts
  • Employee Benefit Managers

Attendees would represent organizations including:

  • Health Plans 
  • Provider Networks
  • Employers
  • Third Party Administrators
  • Pharmaceutical Organizations
  • Health Benefit Consultants
  • Pharmaceutical Consultants
  • Solutions Providers 
  • Care Management Organizations
  • Behavioral Health Organizations
  • Associations, Institutes and Research Organizations 
  • Government Agencies
  • Media
  • Other Interested Parties

Combating Controlled Substance Abuse: Link Between CS Score and Health Outcomes 
  Individual Registration Fee: $195. Post-event materials, with video syncing slides and recorded audio, plus presentation pdf file: $45 for attendees; $260 for non-attendees after the event. Register online or download the event brochure.
Register Now   Corporate Site licensing also available. Click here to register or call 209.577.4888 We look forward to your participation in this event!
Catherine Starner

Catherine Starner, PharmD, BCPS
Principal Health Outcomes Researcher
Prime Therapeutics
  Catherine Starner, PharmD, BCPS is the Principal Health Outcomes Researcher for Prime Therapeutics. Cathy uses integrated medical and pharmacy data to study the impact of pharmacy programs and identify the most cost-effective treatments. Her research helps improve every aspect of pharmacy benefit management.

Cathy joined Prime Therapeutics as a Senior Health Outcomes Researcher in 2007. Previously she was Assistant Professor with the University of Minnesota College of Pharmacy for five years. She also continues as Clinical Assistant Professor, Experimental and Clinical Pharmacology with the University.

She received her Doctor of Pharmacy (PharmD), Geriatrics from the University of Minnesota-Twin Cities. Her Residency was with the Geriatric Pharmacy, Veteran Affairs Medical Center, University of Minnesota and her Fellowship was in Geriatric Pharmacotherapy, College of Pharmacy Institute for the Study of Geriatric Pharmacotherapy, University of Minnesota.
HealthcareWebSummit events from MCOL  
1101 Standiford Ave. Suite C-3 Modesto, CA 95350
Phone 209.577.4888  | e-Mail  |  Fax 209.577.3557
copyright , MCOL All rights reserved. Terms of Use apply to this site and participation in events.